换一批The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
第一作者：
Roswitha,Forstpointner
第一单位：
Department of Internal Medicine III, University of Munich, Klinikum Grosshadern, Marchioninistr. 15 81377 München, Germany.
作者：
医学主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗体, 单克隆(Antibodies, Monoclonal);抗体, 单克隆, 鼠源性(Antibodies, Monoclonal, Murine-Derived);抗肿瘤药, 烷基化(Antineoplastic Agents, Alkylating);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);环磷酰胺(Cyclophosphamide);女(雌)性(Female);人类(Humans);淋巴瘤, 滤泡性(Lymphoma, Follicular);淋巴瘤, 膜细胞(Lymphoma, Mantle-Cell);男(雄)性(Male);中年人(Middle Aged);米托蒽醌(Mitoxantrone);前瞻性研究(Prospective Studies);复发(Recurrence);存活率分析(Survival Analysis);阿糖腺苷(Vidarabine)
DOI
10.1182/blood-2004-04-1323
PMID
15284112
发布时间
2022-03-10
- 浏览117
Blood
3064-71页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
